Evidence map›Paper›PMID 39273415›Full record

ArticleInternational journal of molecular sciences2024

Renoprotective Effects of Daprodustat in Patients with Chronic Kidney Disease and Renal Anemia.

Yoshitaka Shimada, Yuichiro Izumi, Yukiko Yasuoka, Tomomi Oshima, Yasushi Nagaba, Masayoshi Nanami, Jeff M Sands, Noriko Takahashi, Katsumasa Kawahara, Hiroshi Nonoguchi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yoshitaka ShimadaDivision of Internal Medicine, Kitasato University Medical Center, 6-100 Arai, Kitamoto 364-8501, Saitama, Japan.
Yuichiro IzumiDepartment of Nephrology, Kumamoto University Graduate School of Medical Sciences, 1-1-1 Honjo, Chuo-ku, Kumamoto 860-8556, Kumamoto, Japan.ORCID 0000-0003-0827-9619
Yukiko YasuokaDepartment of Physiology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara 252-0374, Kanagawa, Japan.ORCID 0000-0002-9380-1653
Tomomi OshimaDepartment of Physiology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara 252-0374, Kanagawa, Japan.
Yasushi NagabaDivision of Internal Medicine, Kitasato University Medical Center, 6-100 Arai, Kitamoto 364-8501, Saitama, Japan.
Masayoshi NanamiDepartment of Cardiovascular and Renal Medicine, Hyogo Medical University, 1-1 Mukogawa-cho, Nishinomiya 663-8501, Hyogo, Japan.
Jeff M SandsRenal Division, Department of Medicine, Emory University School of Medicine, 1639 Pierce Drive, WMB Room 1107, Atlanta, GA 30322, USA.ORCID 0000-0001-9822-0607
Noriko TakahashiDepartment of Physiology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara 252-0374, Kanagawa, Japan.ORCID 0000-0003-1025-1690
Katsumasa KawaharaDepartment of Physiology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara 252-0374, Kanagawa, Japan.
Hiroshi NonoguchiDivision of Internal Medicine, Kitasato University Medical Center, 6-100 Arai, Kitamoto 364-8501, Saitama, Japan.ORCID 0000-0001-7831-7380

Funding

Grant-in-Aid for Scientific Research from the Ministry of Educatin, Culture, Spoerts, Sciences ahd Technology of Japan 24K11431Kitasato University Medical Center H24-011
6 · The paper itself

Abstract

Many large-scale studies revealed that exogenous erythropoietin, erythropoiesis-stimulating agents, have no renoprotective effects. We reported the renoprotective effects of endogenous erythropoietin production on renal function in ischemic reperfusion injury (IRI) of the kidney using the prolyl hydroxylase domain (PHD) inhibitor, Roxadustat. The purpose of this study was to investigate the effects of daprodustat on the progression of chronic renal failure. We retrospectively investigated the effects of daprodustat on the progression of chronic renal failure and renal anemia in patients with stages 3a-5 chronic kidney diseases (estimated glomerular filtration rate, eGFR < 60 mL/min/1.73 m

Indexed as

AnemiaGlomerular Filtration RateGlycineRenal Insufficiency, ChronicAgedAged, 80 and overBarbituratesFemaleHumansKidneyMaleMiddle AgedRetrospective StudiesBarbituratesGlycineGSK1278863deglycosylationdistal tubuleserythropoietinhypoxiaPHD inhibitorproximal tubulesrenal erythropoietin-producing interstitial cells

Identifiers

PMID39273415
PMCPMC11395309

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.